AG
BCAX

Algert Global’s Bicara Therapeutics BCAX Stock Holding History

Algert Global’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.92M Sell
233,232
-97,601
-30% -$2.18M 0.08% 413
2026
Q1 		$6.58M Buy
330,833
+12,564
+4% +$216K 0.1% 354
2025
Q4 		$5.36M Buy
318,269
+300,679
+1,709% +$5.14M 0.08% 409
2025
Q3 		$278K Buy
+17,590
New +$197K ﹤0.01% 1011

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Algert Global's BCAX Position: Q2 2026 in Review

Algert Global reduced its Bicara Therapeutics (BCAX) stake by 30% in Q2 2026, selling an estimated $2.18M and leaving 233,232 shares worth $6.92M. The position accounts for 0.08% of the portfolio, ranked #413.

Algert Global first reported a position in BCAX in Q3 2025 and has held it in 4 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Algert Global held 233,232 shares of Bicara Therapeutics worth $6.92M as of Q2 2026.
  • Algert Global sold 97,601 Bicara Therapeutics shares in Q2 2026, an estimated $2.18M.
  • Bicara Therapeutics made up 0.08% of Algert Global's portfolio in Q2 2026, its #413 holding.
  • Algert Global first reported a position in Bicara Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.